Johnson & Johnson Fined $572 Million Over Opioid Drug Crisis

Healthcare, opioid epidemic and drug abuse concept with the map of USA filled with oxycodone and hydrocodone pharmaceutical pills on the American flag
The verdict could have huge implications as other states and communities target pharmaceutical companies.

HealthDay News — An Oklahoma judge ruled against one of America’s biggest companies, Johnson & Johnson, and levied a fine of $572 million as part of the first trial of an opioid maker sued by a state for the human and financial costs of the prescription painkiller crisis.

The verdict could have huge implications as other states and communities target pharmaceutical companies for the epidemic of opioid abuse that has claimed hundreds of thousands of lives in the United States since 2000. More than 2000 lawsuits on the issue are aimed at various drug companies.

Related Articles

Oklahoma has accused Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, of creating a public nuisance that cost the state billions of dollars and caused thousands of deaths. Johnson & Johnson has denied any wrongdoing. The state had asked for nearly $17.2 billion over 30 years to tackle the problem. Cleveland County District Judge Thad Balkman released his decision Monday afternoon.

“The opioid crisis is an imminent danger and menace to Oklahomans,” Balkman, of Cleveland County District Court, said in delivering his decision, The New York Times reported.

Lawyers representing the state applauded the decision. “We’ve shown that J&J was at the root cause of this opioid crisis,” Brad Beckworth, the lead attorney for the state, told the Times. “It made billions of dollars from it over a 20-year period. They’ve always denied responsibility and yet at the same time they say they want to make a difference in solving this problem. So do the right thing: come in here, pay the judgment.”

J&J disputes the notion that it helped create the opioid abuse epidemic, however. “Janssen did not cause the opioid crisis in Oklahoma, and neither the facts nor the law support this outcome,” Michael Ullmann, general counsel and executive vice president of J&J, said in a statement. “We recognize the opioid crisis is a tremendously complex public health issue and we have deep sympathy for everyone affected.”

The New York Times Article

This article originally appeared on Medical Bag